DrugPatentWatch Database Preview
Drugs in Development Information for Penclomedine
Development status for investigational drug Penclomedine: Sponsors, patents, clinical trial progress
Penclomedine is an investigational drug.
There have been 6 clinical trials for Penclomedine.
The most recent clinical trial was a Phase 2 trial, which was initiated on September 1st 2013.
The most common disease conditions in clinical trials are Neoplasms, Neoplasms, Second Primary, and Brain Neoplasms. The leading clinical trial sponsors are National Cancer Institute (NCI), DEKK-TEC, Inc., and Icahn School of Medicine at Mount Sinai.
There are fifty-nine US patents protecting this investigational drug and five hundred and twelve international patents.
Summary for Penclomedine
| US Patents | 59 |
| International Patents | 512 |
| US Patent Applications | 98 |
| WIPO Patent Applications | 83 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2013-09-01) |
| Vendors | 8 |
Recent Clinical Trials for Penclomedine
| Title | Sponsor | Phase |
|---|---|---|
| A Phase I Study of DM-CHOC-PEN in Pediatric and Adolescent Subjects With Advanced Cancers | DEKK-TEC, Inc. | Phase 1 |
| Study of 4-Demethyl-4-cholesteryloxycarbonylpenclome in Patients With Brain Tumors | Detroit Clinical Research Center, Farmington Hills, Lansing and Owasso, MI | Phase 2 |
| Study of 4-Demethyl-4-cholesteryloxycarbonylpenclome in Patients With Brain Tumors | Icahn School of Medicine at Mount Sinai | Phase 2 |
Clinical Trial Summary for Penclomedine
Top disease conditions for Penclomedine
Top clinical trial sponsors for Penclomedine
US Patents for Penclomedine
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Penclomedine | Start Trial | Methods and systems for predicting cancer outcome | H. Lee Moffitt Cancer Center and Research Institute, Inc. (Tampa, FL) University of South Florida (Tampa, FL) | Start Trial |
| Penclomedine | Start Trial | Methods and compositions for the treatment of a host with a cellular proliferative disease | Matrix Pharmaceutical, Inc. (Menlo Park, CA) | Start Trial |
| Penclomedine | Start Trial | Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof | Pharmacia & UpJohn AB (Stockholm, SE) | Start Trial |
| Penclomedine | Start Trial | Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof | Pharmaciaand Upjohn AB (Stockholm, SE) | Start Trial |
| Penclomedine | Start Trial | Self-emulsifiable formulation producing an oil-in-water emulsion | Yissum Research Development Company of the Hebrew University of Jerusalem (Jerusalem, IL) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Penclomedine
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Penclomedine | European Patent Office | 1894131 | 2025-02-25 | Start Trial |
| Penclomedine | World Intellectual Property Organization (WIPO) | 2005083128 | 2024-02-25 | Start Trial |
| Penclomedine | World Intellectual Property Organization (WIPO) | 2006093507 | 2024-02-25 | Start Trial |
| Penclomedine | Austria | 220894 | 2013-12-29 | Start Trial |
| Penclomedine | Australia | 1438695 | 2013-12-29 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
